Diagast Bundled BLA 125615, 125619 to 125626
The FDA has issued an update regarding a bundled Biologics License Application (BLA) for Diagast, covering license numbers 125615 and numbers 125619 through 125626.
Diagast, regulatory affairs personnel managing blood-related biologics, and clinical laboratories or blood centers utilizing these specific licensed products.
The bundling of these BLAs typically suggests a streamlined administrative or regulatory approach to products within the same family or manufacturing process. For regulatory professionals, this consolidation may simplify lifecycle management and post-approval reporting requirements for the associated blood grouping reagents or biological products.
Regulatory teams should confirm that internal documentation and product labels for these specific BLAs align with the consolidated filing status. QA should ensure these license numbers are correctly referenced in any upcoming annual reports or post-market surveillance activities.